Thirty-two of the 55 patients with advanced stage BRAF mutated NSCLC cases were treated with anti-BRAF targeted therapy during their treatment course, among whom 30 harbored V600E mutation, 1 harbored K601E mutation and 1 harbored T599dup. Here, BRAF is linked to non-small cell lung carcinoma.